American biotech startup Moderna has said it is ready to launch the final phase of clinical studies of its vaccine for the prevention COVID-19 with the participation of 30 thousand volunteers, reports Reuters.
The study should begin in July, and its primary endpoint will be the reduction in the number of cases COVID-19 among immunized secondary point – reducing the number of cases with severe (requiring hospitalization).
For research to be used the dose of 100 µg, as determined previously as the optimal from the point of view of safety and immunogenicity.
According to the company, it already has the required number of doses of vaccine to conduct a phase 3 study. In General it is willing to release up to 500 million doses per year, with a possible increase in production capacity to 1 billion a year in 2021.
The drug Modernа under the working title of the mRNA-1273 is considered the first vaccine against novel coronavirus infections, the developer stated about the readiness of the product for clinical studies in February, 42 days after the sequencing of the genome of SARS-CoV-2. mRNA-1273 contains a messenger RNA carrying information about the structure of the coronavirus surface protein, when introduced into the body it triggers the production of antibodies to this protein.